{"name":"TORL Biotherapeutics, LLC","slug":"torl-biotherapeutics-llc","ticker":"","exchange":"","domain":"torlbiotherapeuticsllc.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_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?oc=5","date":"2025-10-07","type":"trial","source":"PR Newswire","summary":"TORL BioTherapeutics Secures $96M Series C Financing and Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2025 European Society of Medical Oncology","headline":"TORL BioTherapeutics Secures $96M Series C Financing and Presents Updated Phase 1 Results of Novel Claudin 6 Targeted An","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQakpsT0NjSmNHcS1FR1lOZ05HNFZOUVB3d0JQWmdQQThMMWtqdTNveGIzcVV5YVNLYzFLcHhLUTg5cXlYdGRlNGpHcEtkTV95aDVHYl9DeFVLaVVGdUhsLS1kbVVtOU5EcXBSSVhGeko5SERNenhiVzhIY1BtSFRzQTNtdXFXZExRNlFvRkRjM0VHTklhemJ2d2hMa0puTGV0MkFBSE9zaFBYTFJydFRPVzlNcVVlMWk2SXB5RFRraDhnR1ZkWHJJa3VOeWVjYVZJakNKM0hueF8?oc=5","date":"2025-06-09","type":"pipeline","source":"PR Newswire","summary":"TORL BioTherapeutics Announces Appointment of Anna Berkenblit, MD, MMSc, as Board Member - PR Newswire","headline":"TORL BioTherapeutics Announces Appointment of Anna Berkenblit, MD, MMSc, as Board Member","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOV1JMejR5UE9MdDlpYnhyT05xVWJXdGZpbThLaWdmTjlxSEd0LUxCTlZpLV83VlF2MmFTTG1jSE1JQ3FZLWh3UXlsd2R2QTZwY1BlLURMVUt5ZW9acDBSNVVTdGVGdW96dlJiSkhLbGZENEozemUzYzVDUk1HM0ZXUW9FMllGOFRlbXlGTFVHTWk4Zk1oWWVlaUtfUnd3RE1HWnhzajVfX0lZeUtfQ0swZg?oc=5","date":"2024-12-02","type":"pipeline","source":"Contract Pharma","summary":"TORL BioTherapeutics Appoints Aran Maree as Chief Medical Officer - Contract Pharma","headline":"TORL BioTherapeutics Appoints Aran Maree as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AJBVV95cUxOTkhOYUQzand4elVXSTJUd3p4ckRaaGJleERCbWRULU1nVVBwVV9Ud1YwSFFuN1VjbVR2S2tfaTJCWFBsUmtvTUNSazdNNldIOXBPTUtxWHR0cWJYeWt0ZjFEbFlKTWhqWGJ5ZDJXUkV1R21DZVY2VDJmZ053c2tsNUE2RkZ6QV9ZaHVlTHJGRzJjNFdaMk82Mlp3SWROS0xUT0RXNGI4MFplVllMcDF1S2R1LV91aGhGU29zc0pOaXRXcWNJYXpCSEFINGlPZW5WVS1yWG5hZE9OOXJweENUa1pXaWZNWk9QX3lDbnJveTBTUEdTSG52cUl2d1pLZXdLS1c0YXR4OHc5eUl6SnR4bERRRWxuWjNya0VhY3R2N1MwT0x0VGliRTFDdlVHbGhqdU1WQWdnVEtqd0FPRC1ZUWlER1VhZmllNTRzM1pzMkFibm4yY1pjSQ?oc=5","date":"2024-12-02","type":"trial","source":"PR Newswire","summary":"TORL BioTherapeutics Announces Appointment of Aran Maree, M.D., as Chief Medical Officer and Initiates TORL-1-23 Registration-Enabling Phase 2 Study in Platinum-Resistant Ovarian Cancer - PR Newswire","headline":"TORL BioTherapeutics Announces Appointment of Aran Maree, M.D., as Chief Medical Officer and Initiates TORL-1-23 Registr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxNbFRKcU1UY01ia2ZXRXZ2d3B1RkxrZlF3d2ZOdjcwRVRBMkRsbTdRV3laZjdKcjd1SlVHX2FBUW1EdE1VRWN0MW5ZRTUwT3JJcFJEVzl2ZVp1SnFPQjh1LTJTNFhxbVdlSjFRSTRMaV9aOEtvc2dWMXVoSHpyZk5IYVY2Ymg3OFB3OEJMeVQ4czFkZTJPOWE1Y3ZQUG9yUHVSeHE1YUNockprUWd6bU5odjBGYnZrVjFTS0NCRjhGYzFnTmJaNnl1UUZSSHBSQkNwYTE0YUptQkM0U3FSbFdhWDFHYXl1aWxWM3FYenRaV1F1N2JmNDZ1UVM2VHRBLTV6NE01NWp5ZXVEUC1rMVM1QnQxSTlJYkdXLVdmZkxCVF9jazlkU0xudVBNOHd5dkhrb281Njd3UnlBYXhqNmVnLUlTV3pvcm44SEtSMXh3?oc=5","date":"2024-09-15","type":"trial","source":"PR Newswire","summary":"TORL BioTherapeutics Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2024 European Society of Medical Oncology Congress - PR Newswire","headline":"TORL BioTherapeutics Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQUFdvcWFNV0N3LU9IVDBobUR1T2R6RkxsTHVYUXFDZ3hQZWgwbTN0U1JzTHF0Wl9peVQyZXRRZWFWNDl2ekt1dWlxSm5sMnotbS1feFVVa0NSQTFwbFQ1NUhUVGFKcDFtVlRhWkQ0QVdHcm1iQjZOOWpZNVpkYW5fWnh6b09QVzBMYmF3QU9lc09vdG1RR1hWRlI3dG5WRHJBSmFNZnFoand2RHpUQWVuUHpKMlM?oc=5","date":"2024-04-10","type":"pipeline","source":"Contract Pharma","summary":"TORL BioTherapeutics Closes Oversubscribed $158M Series B-2 Financing - Contract Pharma","headline":"TORL BioTherapeutics Closes Oversubscribed $158M Series B-2 Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxQbk9ZNjYxdTFnM1JuOTlXcjUzcTdOZ2Q1NEpfYzNJbFhXQkdCelphY1lPWG4xSEpTdGNOX05OSVhHY1N2bThjRXRWVThRR25zeXNHSmhkVjMyd1JfUENJMEZyZXM5Z0dGOGhCMzlqOXBkblZHRy03Yi1VQWtaVW1CMDVHeVI3Y25wNS1ubFd4SlJiTzNreGtWY0NDbUhUNHVmb1FaZ0RNdEZsblB1cjlqR2NTdmlsWWViSk9MVzNPZmRpWWxXX3ZBVmg5Z1I4VDBlNlF6WFZDYi1QRk1tRUlEWWdQT3dRcVo5VWRYZXUyeExidFBZV0VsY21sUWhzV002b0lTTFg5bGJ6YWl3bTRJbW5ZQzJZZTVCdVFzcnhBTzdNakduTVIzYXZFLWU2NTNVLTNMaUFHdHRlb0EyY09UQU9wLThTR2IybjJRUXRB?oc=5","date":"2024-04-10","type":"pipeline","source":"PR Newswire","summary":"TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline - PR Newswire","headline":"TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of i","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQQTVkNE1adzJfakdHaWNHN25obHp0UFFUTzcwYjR6WURFX2xVUkI1Q3c3Q1ZKNUhIby1mUGhlWWl2TTJDRmNuSGpaUktkS0NSbXlpb0g5NUczaFd1T3hBU3pqaHptUGVOdC12NWt4RjM1U2VLYll4OGR2MjFkemFzOTk0RkNsTF9iTVR3dDlnenhJSUpMR2xqNjNwN24?oc=5","date":"2024-01-12","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Former Celgene CEO Alles takes the top job at TORL - Fierce Biotech","headline":"Chutes & Ladders—Former Celgene CEO Alles takes the top job at TORL","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxOZGhBTUtPejNSUTdmczhpSmRvb0ZxNWV5bWF0REF6UEtnajdWcWFkLUp6RVY5Q3RKYnhrVGNGcHR1LV9iQnJFUDNqVVVsVVdUR2FKdXpmc2czemJDdGdBUVRIMFBOX19oU3BGV242aFFldFF6SXljQTZ1ZUtldDZLbnFFWXFRcTdNeXVrTndLaVBSbzRZWWs1d1piVVZ0VGlCajNjZlV0ZmJRMm1qTUVZTGV6b3JvX0w4Y0FPTk9YOTNSOFNFeWYtOWFLWDFpdDRVRUpGMWJqM0Z4bzA2UTZJZ08waDdNMDNJUlhLZHgwYlFTOGlXZHBnQjRCWlhoQTJ5R3daSEtvNVRZeC1KMW0wS1d3Nk8tNjROQ1pJVUExMGhZdnlrZVNyU2ZmSkd1eVNwN2hNdjNJalVXTlQ4bWVCZGh3?oc=5","date":"2024-01-09","type":"pipeline","source":"PR Newswire","summary":"TORL BioTherapeutics Announces Appointment of Mark J. Alles as Chairman and Chief Executive Officer; Highlights Significant Progress of its Oncology Clinical Programs - PR Newswire","headline":"TORL BioTherapeutics Announces Appointment of Mark J. Alles as Chairman and Chief Executive Officer; Highlights Signific","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQcjRUWXFFY1V5akVoOHZ6dWh0WDRKRUJpN0ttQjVyc0QzaV95aUpMLWNWUjcybkxhb3VIY1lGVV94VzlPeF9CdWQwaGZBR3Z3c3o4c21DY0puWHRtOG1sZE1BVEFvVE1ZaTNDMkZPS19MSUg3bExacTREMVFaZUdxQ1R4a2ozb21lVU9Jdnl5RWpsQ1RTQjZGenpOMGY4MkFa?oc=5","date":"2023-04-14","type":"pipeline","source":"BioPharma Dive","summary":"A biotech startup with big-name backers aims to create new cancer medicines - BioPharma Dive","headline":"A biotech startup with big-name backers aims to create new cancer medicines","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}